Financial Performance - Total revenue for 2024 reached RMB 826.71 million, a slight increase of 0.80% compared to the previous year[4] - Operating profit was RMB -565.84 million, a decrease of 47.42% year-over-year[4] - Net profit attributable to shareholders was RMB -511.60 million, down 28.68% from the previous year[4] - Basic earnings per share decreased by 32.01% to RMB -2.60[4] Assets and Equity - Total assets at the end of 2024 were RMB 8,144.11 million, a decline of 9.47% from the beginning of the year[4] - Shareholders' equity attributable to the parent company decreased by 10.44% to RMB 6,659.97 million[4] Operational Challenges - The company faced increased operational costs due to investments in technology and asset depreciation[7] - The decline in key performance indicators was attributed to slower growth in routine testing business and increased costs from acquisitions and R&D[9] Strategic Focus - The company is focusing on enhancing product lines and technology integration through acquisitions and new projects[7] Investor Advisory - Investors are advised to be cautious as the financial data is preliminary and subject to change upon final audit[10]
东方生物(688298) - 2024 Q4 - 年度业绩